NCT06144125 Prothrombin Complex Concentrate vs Fresh Frozen Plasma in Goal-directed Bleeding Management in Cardiac Surgery
| NCT ID | NCT06144125 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Konkuk University Medical Center |
| Condition | Cardiac Valve Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2026-03-27 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 100 participants in total. It began in 2026-03-27 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary endpoint of this study is the completion time of hemostasis treatment when administered Fresh frozen plasma (FFP) and frozen powder coagulation factor concentrate (PCC) in goal-directed bleeding management for cardiac surgery.
Eligibility Criteria
Inclusion Criteria: * patients undergoing cardiac surgery Exclusion Criteria: * thrombocytopenia * oral anti-coagulant * anti platelet agents
Contact & Investigator
Tae-Yop Kim, MD PhD
PRINCIPAL INVESTIGATOR
Konkuk University Medical Center
Frequently Asked Questions
Who can join the NCT06144125 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 75 Years, studying Cardiac Valve Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06144125 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06144125 currently recruiting?
Yes, NCT06144125 is actively recruiting participants. Contact the research team at taeyop@gmail.com for enrollment information.
Where is the NCT06144125 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT06144125 clinical trial?
NCT06144125 is sponsored by Konkuk University Medical Center. The principal investigator is Tae-Yop Kim, MD PhD at Konkuk University Medical Center. The trial plans to enroll 100 participants.